Results 301 to 310 of about 5,057,415 (322)

Pharmacological effects of osimertinib on a chicken chorioallantoic membrane xenograft model with the EGFR exon‐19‐deleted advanced NSCLC mutation

FEBS Open Bio, EarlyView.
Osimertinib reduces angiogenesis and PDL1 expression in in ovo tumors, transforming them into ‘cold tumors’ with lower immune activity. Anatomopathological and transcriptomic analyses highlight its therapeutic impact on tumor biology. This study underscores osimertinib's potential to reshape the tumor microenvironment and provides insights into its ...
David Barthélémy, Arnaud Vigneron, Xavier Rousset, Jérome Guitton, Emmanuel Grolleau, Margaux Raffin, Julie Balandier, Gaëlle Lescuyer, Mathilde Bardou, Florence Geiguer, Sébastien Couraud, Claire Bardel, Jean Viallet, Nazim Benzerdjeb, Léa Payen   +14 more
wiley   +1 more source

Targeting Latent HIV Reservoirs: Effectiveness of Combination Therapy with HDAC and PARP Inhibitors. [PDF]

Viruses
Tibebe H, Marquez D, McGraw A, Gagliardi S, Sullivan C, Hillmer G, Narayan K, Izumi C, Keating A, Izumi T.   +9 more
europepmc   +1 more source

Targeting Signaling Excitability in Cervical and Pancreatic Cancer Cells Through Combined Inhibition of FAK and PI3K. [PDF]

Int J Mol Sci
Chen CC, Wang S, Yang JM, Huang CH.
europepmc   +1 more source

Targeting PI3K Signaling to Overcome Tumor Immunosuppression: Synergistic Strategies to Enhance Cancer Vaccine Efficacy. [PDF]

Vaccines (Basel)
Cui R, Luo Z, Zhang X, Yu X, Yuan G, Li X, Xie F, Jiang O.   +7 more
europepmc   +1 more source

Bibliometric and Visualization Analysis of DprE1 Inhibitors to Combat Tuberculosis. [PDF]

Drug Des Devel Ther
Wang Q, Fu H, Zhang Y, Zhang M, Xu J, Fu J.   +5 more
europepmc   +1 more source

Efficacy and safety of PD-1/PD-L1 inhibitors as first-line treatment for esophageal squamous cell carcinoma: a systematic review and meta-analysis. [PDF]

Front Immunol
Ren W, Zhang H, Li Y, Sun W, Peng H, Guo H, Hou T, Wang M, Hu Z, Wu T, Liu B.   +10 more
europepmc   +1 more source

Drug design for cyclin-dependent kinase 9 (CDK9) inhibitors <i>in silico</i>. [PDF]

Biochem Biophys Rep
Asamitsu K, Hirokawa T, Okamoto T.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Specificity and mechanism of action of some commonly used protein kinase inhibitors.

Biochemical Journal, 2000
The specificities of 28 commercially available compounds reported to be relatively selective inhibitors of particular serine/threonine-specific protein kinases have been examined against a large panel of protein kinases.
S. Davies, Helen Reddy, M. Caivano, P. Cohen   +3 more
semanticscholar   +1 more source

Matrix metalloproteinases and their inhibitors in connective tissue remodeling

The FASEB Journal, 1991
Matrix metalloproteinases are an important group of zinc enzymes responsible for degradation of the extracellular matrix components such as collagen and proteoglycans in normal embryogenesis and remodeling and in many disease processes such as arthritis,
J. Woessner
semanticscholar   +1 more source

Thirty years of HDAC inhibitors: 2020 hindsight.

Journal of Medicinal Chemistry, 2020
It is now thirty years since the first report of a potent zinc-dependent histone deacetylase (HDAC) inhibitor appeared. Since then, five HDAC inhibitors have received regulatory approval for cancer chemotherapy, while many others are in clinical ...
Terence C. S. Ho, A. Chan, Arasu Ganesan
semanticscholar   +1 more source